Clinical Trials Logo

Diagnosis clinical trials

View clinical trials related to Diagnosis.

Filter by:

NCT ID: NCT06072820 Not yet recruiting - Endometriosis Clinical Trials

Analytical Evaluation of the Endotest® Diagnostic

ENDORepro
Start date: October 2023
Phase: N/A
Study type: Interventional

This is an interventional with minimal risks and constraints (RIPH 2 in France), prospective, longitudinal, non-randomized, multicenter study. The present study will allow us to evaluate multiple factors assessing the Endotest® Diagnostic accuracy and its possible limitations. To characterize the Endotest® Diagnostic, the following parameters will be evaluated: - Repeatability: the verification of the invariability of its results without condition changes, - Circadian cycle: whether the circadian cycle affects the determination of the signature, - Intermediate fidelity: the verification of the invariability of its results with an operator change, - Interferences: the impact of different interferences on its results, - Stability: the possible modification of its results depending on the samples conditions of storage. The acts and procedures performed in this research will be divided into three visits: - Inclusion visit: performance of 4 Endotest® Diagnostics (3 at the visit and 1 at home) by the 60 included subjects, - "Circadian cycle" visit: performance of 17 Endotest® Diagnostics (14 at the visit and 3 post-visit at home) by 6 subjects selected after evaluation of the results of the inclusion visit, - "Repeatability-intermediate fidelity-interference-stability" visit: realization of 17 Endotest® Diagnostic by 10 or 16 subjects, depending on the results of the impact of the circadian cycle on the saliva signature. These subjects will be selected according to the results of the inclusion visit, excluding those who participated in the circadian cycle visit.

NCT ID: NCT06028087 Not yet recruiting - Multiple Myeloma Clinical Trials

Real-World Mapping Antithrombotic Regimens in MM Patients on Treatment

Start date: December 2023
Phase:
Study type: Observational

The goal of this observational study is to learn about antithrombotic regimens in Multiple myeloma patients. The main question it aims to answer is the efficacy of different types of thromboprophylaxis (antiplatelet agents, heparins, oral anticoagulants) in preventing venous thromboembolism (VTE).

NCT ID: NCT06025240 Not yet recruiting - Frailty Clinical Trials

Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients

HLA-AB
Start date: September 1, 2023
Phase:
Study type: Observational

The purpose of this study is to assess a new test to detect antibodies which may form following kidney transplant. These antibodies can be difficult to detect as they do not cause any symptoms but can lead to kidney damage. A new blood test will be performed alongside existing antibody tests to see how well the test functions in comparison and to see how well it is able to distinguish between inflammation caused by antibodies and other sorts of inflammation such as a urinary tract infection. The investigators also want to determine whether it is predictable whom will develop antibodies after a transplant and use these results to change the current way patients are monitored for antibodies after receiving a transplant. In addition to this, the investigators want to establish if patients over 60 years of age are relatively protected against immunological events such as rejection compared to patients who are under 60 years of age. The results could potentially lead to using a different immunosuppression regime based on which population age group patients belong to and lowering the risks associated with these drugs.

NCT ID: NCT05979350 Not yet recruiting - Pneumonia Clinical Trials

Metagenomic NGS for Diagnosis of Pneumonia

Start date: August 1, 2023
Phase: N/A
Study type: Interventional

In this randomized controlled trial, we aim to evaluate the efficacy of incorporating mNGS in the management of pneumonia on efficiency and accuracy of causative pathogen identification, proportion of participants with effective antimicrobial therapy, length of hospitalization, and mortality.

NCT ID: NCT05974163 Not yet recruiting - Critical Illness Clinical Trials

Development of an AI-based Emergency Imaging Multi-Disease Rapid Joint Screening System

Al-MDS
Start date: August 1, 2023
Phase:
Study type: Observational

Introduction: Early and rapid diagnosis of etiology is often an important part of saving the lives of patients in emergency department. Chest CT is an important examination method for emergency diagnosis because of its fast examination speed and accurate localization. Traditional medical imaging diagnosis relies on radiologists to report in a qualitative and subjective manner. Through the interdisciplinary combination of clinical, imaging and artificial intelligence, the integration of multi-omics data, the construction of large-scale language models, and the construction of the auxiliary diagnosis support system of "one check for multiple diseases" provide new ideas and means for the rapid and accurate screening of emergency critical diseases. Method: Study design Investigators retrospectively collected cardiovascular, respiratory, digestive, and neurological CT images, demographic data, medical history and laboratory date of emergency department patients during the period from 1 January 2018 and 30 December 2024. Regularly carry out standardized follow-up work, and complete the collection and database establishment of clinical-imaging multi-omics data of patients attending emergency department.The inclusion criteria are:1. adult emergency patients with cardiovascular, respiratory, digestive, and nervous system diseases; 2. These patients had CT images. Patients with incomplete clinical or radiographic data were excluded from the analysis. Regularly carry out standardized follow-up work, and complete the collection and database establishment of clinical-imaging multi-omics data of patients attending emergency department. Based on the collected medical text data, an artificial intelligence large-scale language model algorithm framework is built. After the structure annotation of chest CT images is performed by doctors above the intermediate level of imaging, the Transformer deep neural network is trained for CT image segmentation, and a series of tasks such as structural structure segmentation, damage detection, disease classification and automatic report generation are developed based on Vision Transformer self-attention architecture mechanism. A multi-disease diagnosis and treatment decision-making system based on chest CT images, clinical text and examination multimodal data was constructed and validated. Disscusion Emergency medicine deals mainly with unpredictable critical and sudden illnesses. Patients who come to the emergency department for medical treatment often have acute onset, hidden condition, rapid progress, many complications, high mortality and disability rate. Assisted diagnosis systems developed by combining clinical text, images and artificial intelligence can greatly improve the ability of emergency department doctors to accurately diagnose diseases. This study fills the blank of CT artificial intelligence aided diagnosis system for emergency patients, and provides a rapid diagnosis scheme for multi-system and multi-disease. Finally, the results will be transformed into clinical application software and used and promoted in clinical work to improve the diagnosis and treatment level.

NCT ID: NCT05948410 Not yet recruiting - Clinical trials for Lower Urinary Tract Symptoms

How Does the Mood of the Patients Change Before and After the Invasive Urodynamic Study?

Start date: October 1, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this study is to learn about the patient's perspective regarding to psychological mood before and after an invasive urodynamic study.

NCT ID: NCT05947565 Not yet recruiting - Clinical trials for Lower Urinary Tract Symptoms

Patient Position and Invasive Urodynamic Study Results in Males

Start date: October 1, 2023
Phase: N/A
Study type: Interventional

The goal of this study is to learn whether the change or patient position might effect the results of invasive urodynamic study in males.

NCT ID: NCT05931055 Not yet recruiting - Ovarian Cancer Clinical Trials

The Effectiveness of Liquid Biopsy in Differential Diagnosis and Early Screening of Epithelial Ovarian Cancer

Start date: January 1, 2024
Phase:
Study type: Observational

At present, there is a lack of effective screening methods. It is urgent to explore new non-invasive detection methods for early diagnosis of epithelial ovarian cancer and non-invasive differentiation methods for benign and malignant ovarian tumors. Liquid biopsy technology has great potential for early screening of tumors. The fragmentation patterns of cfDNA fragments in plasma and the uneven coverage of the genome can indirectly reflect the state of gene expression regulation in vivo. Its characteristics mainly include copy number variation (CNV), Nucleosome footprint, fragment length and motif. The number of proteins in a proteome can sometimes exceed the number of genomes. It includes "structural Proteomics" and "functional Proteomics". At present, research has explored the use of urinary protein biomarkers for early diagnosis of gastric cancer. "Deep Visual Proteomics (DVP)" reveals the mechanism driving tumor evolution and new therapeutic targets for tumors. Using the currently mature low depth WGS sequencing technology, this study aims to explore its clinical application in the differentiation and early screening of epithelial ovarian cancer, as well as monitoring the course of epithelial ovarian cancer, including the detection of minimal residual lesions (MRD) and monitoring of recurrence (MOR). This study also explores the role of urine proteomics in the differentiation of benign and malignant ovarian tumors, early screening and invasiveness of epithelial ovarian cancer, and monitoring the course of epithelial ovarian cancer.

NCT ID: NCT05889312 Not yet recruiting - Cancer Clinical Trials

Assessing Cancer Treatment Response to Therapy Using 18F-FSPG PET

Start date: September 2023
Phase:
Study type: Observational

Prospective single centre non-randomised exploratory observational study to measure changes in tumour cellular redox status with 18F-FSPG PET in stage 3 non-small cell lung cancer (NSCLC) and stage 3 and 4 head and neck squamous cell cancer (HNSCC) at baseline and during standard of care treatment, and to compare this with 18F-FDG PET/CT and RECIST 1.1 response at 12 weeks.

NCT ID: NCT05845112 Not yet recruiting - Tuberculosis Clinical Trials

Start Taking Action For TB Diagnosis

START4ALL
Start date: September 2023
Phase:
Study type: Observational

Globally, tuberculosis (TB) is one of the main causes of death and the leading cause from a single infectious agent. In 2020, an estimated 9.9 million people developed TB and 1.5 million died. Millions of people remain undiagnosed with TB, hindering efforts to end TB. TB tests have inadequate accuracy or performance characteristics for implementation across all populations and settings. None of the tests meet the WHO-Target-Product Profile for TB screening and most need specialized laboratory staff and infrastructure, making them unsuitable for primary health care (PHC). The overall aims for this project are to: 1. Accelerate the introduction/adoption of TB diagnostic tools and test combinations at PHC, for the timely detection of TB and improved linkage to treatment 2. Develop conditions for sustainable and equitable access to TB diagnostics tools and test combinations within PHC, 3. Strengthen global alliances and national partnerships to enable scale-up. The study is split into two major Phases. This application is focused on Phase 1. Specific Phase 1 objectives are to: 4. Evaluate the performance of selected TB diagnostic tools, and 5. Identify TB test combinations that increase the proportion of people diagnosed with bacteriologically confirmed TB. Methods in Brief: Activities will be conducted in Bangladesh, Brazil, Kenya, Cameroon, Malawi, Nigeria, and Vietnam. Each country will study selected priority populations at risk of TB, including adults attending PHC centers and district hospitals; people living with HIV (PLHIV); marginalized populations (internally displaced, refugees and pastoralists), and children. Activities within countries will use standardized protocols for evaluating diagnostic tests and combinations.